Transcatheter Technologies reports six-month follow-up results for pilot study of its ‘truly repositionable’ Trinity TAVI System

19-03-2014 Business Wire HealthComments (0)

GermanyNorthern Europe

Transcatheter Technologies GmbH, an emerging medical device company that is developing a third-generation transcatheter aortic valve implantation (TAVI) system—Trinity—announced today the successful 6-month follow-up results for a pilot study of its Trinity TAVI system that is designed to be the world’s first ‘truly repositionable’ and, therefore, best TAVI system. At six-month follow-up, the mean pressure gradient was reduced from 59 mmHG at the start of t

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top